Agfa HealthCare announced Mark Burgess as President North America Agfa HealthCare, effective October 2022. New appointment joins recently reinvigorated roster of leadership at both global and regional levels.

GREENVILLE, S.C. - November 30, 2022 - (Newswire.com)

Agfa HealthCare announced Mark Burgess as President North America Agfa HealthCare, effective October 2022. Burgess is based in Raleigh, North Carolina.

"Mark Burgess comes to Agfa HealthCare to lead our focus on building and delivering long-term strategic benefits to the North American healthcare provider clients we serve.  He understands the value of working side-by-side with health systems to help them meet their goal to deliver quality patient care," said Nathalie McCaughley, President, Agfa HealthCare. "He and his teams in the U.S. and Canada will expand the company's reach in providing guidance to new and existing clients in implementing and adopting the Agfa HealthCare Enterprise Imaging Platform, to allocate resources effectively, control the total cost of care, and enhance patient-and-provider relationships and satisfaction."

With extensive experience in healthcare information technology, Burgess joined Agfa HealthCare from NextGen HealthCare, where he was Senior Vice President, Ambulatory Markets. He has also held leadership positions at Cerner (now Oracle Cerner) and Allscripts and, throughout his career, managed sales, consulting, product management and corporate strategy. 

"I am very excited to be joining the Agfa HealthCare team as we approach the tipping point of Enterprise Imaging adoption," said Mark Burgess. "I believe that Agfa's unique vision of guiding health systems to improve accessibility and integration of medical imaging will improve their efficiency, collaboration and clinical outcomes across disciplines and geographies. Our platform technology keeps clinicians focused on what matters most: diagnosis and treatment of patients."

About Agfa HealthCare
Agfa HealthCare is transforming the role of medical imaging into a high-impact, data-driven enterprise-wide information flow - supporting health professionals across the globe with secure and scalable imaging data management. The company's mission is to provide the solutions and guiding experience to help clients improve productivity, manage resource allocation, and mitigate complexity and redundant technologies while providing clinical confidence with readily available patient-centric information. 

The company's preeminent product, the Enterprise Imaging Platform, creates an Imaging Health Record™ or IHR, to align with and fulfill a health system's EHR/digital transformation strategy. The IHR provides an unobstructed flow of patient imaging information to help care providers achieve their clinical, operational, and business strategies.

Agfa HealthCare is a division of the Agfa-Gevaert Group which is headquartered in Mortsel, Belgium, and traded on Euronext Brussels (AGFB).

Contact Information:
Miriam Ladin
Marketing and Communication Americas
[email protected]
+1 978 284 7777


Press Release Service by Newswire.com

Original Source: Mark Burgess Named President North America, Agfa HealthCare

BUFFALO, N.Y. - November 30, 2022 - (Newswire.com)

POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2 clinical trial of EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes. Data from this clinical study has been published today in BMC Medicine (https://doi.org/10.1186/s12916-022-02661-1).

EuCorVac-19 is an RBD-based vaccine consisting of POP BIO's Spontaneous Nanoliposome Antigen Particle (SNAP) technology in combination with the adjuvant genetically modified E. coli Monophosphoryl Lipid A (EcML), produced by EuCorVac-19 manufacturer Eubiologics (KOSDAQ: 206650). Use of SNAP technology enables co-delivery, as opposed to co-administration, of antigen with adjuvant, packed in an immunogenic nanoparticle format free of any carrier protein. 

In this Phase II clinical study, 229 participants were enrolled at five clinical sites in South Korea. Healthy adults aged 19-75 without prior exposure to COVID-19 were dosed on day 0 and day 21 between July and October 2021. The most common local adverse events were low-grade injection site tenderness and pain, while the most common systemic adverse events were low-grade fatigue, myalgia, and headache. No clinical abnormalities were detected, and no serious adverse effects were solicited by EuCorVac-19. Adverse events did not increase with the second dosing. On day 42, Spike IgG geometric mean ELISA titers were 0.8, 211, and 590 Spike binding antibody units (BAU/mL) for placebo, low-dose, and high-dose EuCorVac-19, respectively (p < 0.001 between groups). No anti-his-tag antibodies were detected. Neutralizing antibody levels of the low-dose and high-dose EuCorVac-19 groups had FRNT50 geometric mean values of 129 and 316, respectively. Boosting responses and dose responses were observed. Antibodies against the RBD correlated with antibodies against the Spike and with virus neutralization.

The published data shows that in this trial, EuCorVac-19 was well-tolerated and induced antibodies in a dose-dependent manner that neutralizes SARS-CoV-2. The unique liposome display approach of EuCorVac-19, which lacks any immunogenic protein components besides the antigen itself, coupled with the lack of increased adverse events during boosting suggests the vaccine platform is amenable to multiple boosting regimes in the future to help control the ongoing COVID-19 pandemic. 

"The results of this Phase II trial provide critical evidence of the value of the SNAP platform. This data provides invaluable support towards our platform's development, further enabling the creation of new vaccines with the potential to alleviate suffering worldwide," says POP BIO co-founder Jonathan Smyth.

"The unique qualities of the SNAP adjuvant system enabled simple conversion of protein antigens into immunogenic particles that safely induced virus-neutralizing antibodies. We look forward to further study of this technology for the prevention of COVID-19 and other diseases," says company co-founder and study co-author Jonathan Lovell. 

Presently, EuCorVac-19 is undergoing two Phase III clinical studies in simultaneous studies in the Philippines and the Democratic Republic of Congo. EuBiologics is working with international research organizations to expedite recruitment and analyze trial results to accelerate regulatory approval of EuCorVac-19.

POP BIO is developing new vaccine product candidates and is seeking further collaborators around the SNAP technology to make use of the unique qualities of the vaccine platform technology.

POP Biotechnologies (POP BIO): POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from The State University of New York Research Foundation (SUNY-RF), was developed by company founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo).

POP BIO's SNAP Technology: POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of immunogenic particle-based vaccines and immunotherapies directed against infectious diseases and other diseases through the use of cobalt-modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle formation and liposome-display of protein and peptide antigens, resulting in substantial improvements in antigen-specific immune responses.

About EuBiologics: EuBiologics is a South Korean biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens and EcML. The total capacity of COVID-19 vaccine is in the hundreds of millions of doses per year.

About EuBiologics' EuIMT Technology: EuBiologics' Immune Modulation Technology uses genetically engineered Monophosphoryl Lipid A (MLA), termed EcML, a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems. Eubiologics' EcML and POP BIO's SNAP technologies synergize to create potent next-generation vaccines.

Contact Information:
Jonathan Smyth
President
[email protected]
+13152200087


Press Release Service by Newswire.com

Original Source: POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

VNA launched Moving Healthcare Forward Podcast

RED BANK, N.J. - November 30, 2022 - (Newswire.com)

VNA Health Group launched a new healthcare-focused podcast, The Moving Healthcare Forward Podcast, on iTunes and Spotify, as part of their massive strategic initiative and four-year plan to move healthcare forward by making care more equitable, creating the workforce of tomorrow, impacting behavioral health and bringing dignity to aging.

VNAHG President and CEO Dr. Steven Landers hosts The Moving Healthcare Forward Podcast, where he has conversations with leaders in the healthcare space. Together, Landers and his guests will discuss how to address the massive challenges facing the healthcare industry, including how to provide the best care for everyday people, especially the most vulnerable.

"I'm thrilled to launch this podcast," Landers said, "because I know that it will help VNAHG push forward the bold opportunities we have to do good in healthcare, particularly home healthcare. It's also a project close to my heart: As a certified family doctor and geriatrician, The Moving Healthcare Forward Podcast allows me to fuse together my experience in geriatric medicine, home health and palliative care with what I see as my purpose, bridging the gaps in healthcare inequity."

The first episode features an interview with Bill Dombi, President of the National Association for Home Care & Hospice, and is available on iTunes and Spotify. Dombi and Landers discuss the importance of at-home and hospice care and the reimbursement cuts they are facing, Medicare Advantage's lasting impact and incredible recent advancements in care.

"[Some of our advances] may seem like they're incremental," Dombi said on the podcast, "but the way my measuring stick goes, for every time you get kicked back a step, healthcare at home has taken us two steps forward. We're making that progress. When we talk to healthcare providers who work in-home, they basically say the same thing, 'I would not want to work anywhere else.'"

###

ABOUT VNAHG: VNAHG is the nation's second-largest not-for-profit home healthcare organization servicing New Jersey and Ohio. For more than 100 years, they've provided customized care to individuals with chronic diseases and conditions, as well as those who need short-term care. From post-operative nursing and rehabilitation services and speech therapy to wound care and live-in private care — and just about everything in between — their skilled multidisciplinary team delivers the highest level of care possible.

ABOUT DR. STEVEN LANDERS: Dr. Landers is the President and CEO of  VNAHG, along with the host of The Moving Healthcare Forward Podcast. As a certified family doctor and geriatrician, he has a specialized interest in geriatric medicine, home health, hospice and palliative care. Dr. Landers is a graduate of the Case Western Reserve University School of Medicine and the Johns Hopkins University School of Hygiene and Public Health. He has authored several articles on the role of home care in national publications, including the New England Journal of Medicine and the Journal of the American Medical Association.

Contact Information:
Kristi Bridges
CEO & President of The Sawtooth Group
[email protected]
732.492.4520

Elisa Altini
Account Executive at The Sawtooth Group
[email protected]
718.510.6425


Press Release Service by Newswire.com

Original Source: VNAHG President and CEO Launches Healthcare-Focused Podcast

New Platform Prioritizes Transparent Pricing for Care and Procedures While Expanding Direct Payment Experience for Patients

NAPLES, Fla. - November 30, 2022 - (Newswire.com)

HealthMe™ (www.healthmedocs.com) and Tennessee Orthopaedic Clinics, a Division of Tennessee Orthopaedic Alliance, (www.tocdocs.com) announced today a partnership which will provide their patients a next-generation digital payment and price transparency platform. With the goal of helping their patients get the right care at the right cost, Tennessee Orthopaedic Clinics (TOC) will deploy HealthMe to advance their dedication to compassionate, conservative, and prompt care while also exceeding national standards for price transparency.

TOC selected HealthMe to advance their commitment in ensuring that their patients receive information about purchasing healthcare in clear language that does not result in surprise bills. The partnership with HealthMe will offer bundled payment options for those seeking to pay directly for care apart from an in-network insurance plan. Bundle payments benefit self-pay patients, self-insured employers, patients with out-of-network insurance coverage, health sharing ministries, and anyone who bears the out-of-pocket expense for services.

With 32 Board Certified and Board Eligible physicians and surgeons across seven locations in East Tennessee, TOC offers a continuum of care and services to support patients on every step of their recovery—including urgent care services. 

"Supporting our mission to provide our patients with outstanding orthopedic care, we have partnered with HealthMe's new digital payment platform. A key component of this partnership is adopting the most innovative and consumer-friendly technology that will streamline the payment process while eliminating the headaches of confusing paperwork for our direct-pay patients," commented Earl Anderson, CEO. "Our partnership with HealthMe was specifically designed to streamline payments, establish price transparency, and meet the direct-pay needs of our patients."

"Based on their commitment to practice excellence, innovation, and the consumer-focused transformation of healthcare, TOC is the perfect partner to launch our platform," commented Mike Having, MD, HealthMe founder and CEO. "We strive to lessen the burden of time-consuming paperwork for front office and eliminate billing hassles that enable doctors to optimize their time focused on patient care and not be distracted by unnecessary paperwork."

About Tennessee Orthopaedic Clinics 

Proudly serving their orthopedic patients for over 25 years, Tennessee Orthopaedic Clinics, a Division of Tennessee Orthopaedic Alliance, offers comprehensive medical and surgical treatment of bone, joint and soft tissue disorders. Providing quality orthopedic care with a focus on individual needs, positive outcomes and superior patient satisfaction, Tennessee Orthopaedic Clinics proudly employs 32 Board Certified and Board Eligible physicians and surgeons along with a dedicated team of nurses, therapists, trainers and administrators. Serving the entire East Tennessee region, TOC provides compassionate, quality orthopedic care with specialties in spine, foot and ankle, hand and elbow, joint replacement, shoulders, and knees.

https://www.tocdocs.com/

About HealthMe™

HealthMe™ (https://healthmedocs.com) is an online platform that gives medical groups and practices a simple and proven price transparency solution to serve the growing population of Direct-Pay patients and health consumers. Founded and developed by doctors, HealthMe's revenue accelerator platform combines the best features of a consumer-friendly online marketplace with the security of a specialized healthcare payment processing solution. With validated success in automating the process of Good Faith Estimates (GFEs), HealthMe is the first company to provide GFEs in eleven languages. HealthMe helps patients find the best healthcare options while saving money on their care while streamlining the administrative process for overburdened staff. It provides practices with a complete, tested solution focused on "retailing" services for improved growth, staff efficiency, and patient loyalty.

Contact Information:
Kristy [email protected] Parker
Senior Director of Communications and Business Development Tennessee Orthopaedic Clinics
[email protected]

Darrell Atkin
VP Marketing
[email protected]
760-390-6036


Press Release Service by Newswire.com

Original Source: Tennessee Orthopaedic Clinic Selects HealthMe for Price Transparency and Digital Payment Platform

Seattle-based healthcare technology company, the industry leader in OASIS training, has released a premium certificate program that allows clinicians to gain and demonstrate proficiency with OASIS-E

SEATTLE - November 30, 2022 - (Newswire.com)

With OASIS-E launching on Jan. 1, 2023, and so many new clinicians entering home health, organizations need an easy, effective way to train new hires and current staff on OASIS-E data collection and documentation. Because OASIS is a primary tool for determining reimbursement under HHVBP, OASIS errors are costly to organizations and can even pose a threat to patient care. Yet many OASIS training programs require staff to attend in person, or are built under a "train-the-trainer" model, which is inefficient and prone to error.

As the only comprehensive online OASIS-E certificate program currently available, the OASIS-E Comprehensive Excellence Certificate Program sets a new industry standard for OASIS education and excellence. With the program, organizations can set an expected proficiency level with OASIS-E and easily track skill acquisition. By training clinicians on OASIS-E directly and allowing them to demonstrate their proficiency after completion, the certificate program helps organizations foster a higher level of competency while raising the bar on quality and performance.

The OASIS-E Certificate Program builds on MedBridge's extensive experience providing industry-leading online OASIS training to elevate OASIS efficiency and accuracy for new hires and experienced clinicians. The program is integrated with the effective, evidence-based MedBridge OASIS Training Solution, which was designed in partnership with nationally recognized OASIS experts K&K Health Care Solutions and is shown to reduce M-item errors by 28 percent, resulting in $150 additional reimbursement per patient episode. 

The certificate program covers all sections and items within OASIS-E in a concise, engaging online format. Clinicians learn how OASIS data collection impacts both patient care and agency performance, and develop competence through accredited online courses, video lectures, patient demonstrations, case-based quizzes to improve clinical reasoning, and a skills checklist to practice hands-on components of coursework.

"With the launch of OASIS-E, arguably one of the biggest industry changes in recent years, we're truly excited to be able to offer this distinctive certificate program that helps clinicians not only gain proficiency with OASIS-E but also demonstrate their expertise to create an ongoing culture of OASIS excellence," said Joseph Brence, PT, DPT, MBA, FAAOMPT, Head of Clinical Strategy at MedBridge.

Contact Information:
Savannah Isbey
Manager of Content & Creative
[email protected]


Press Release Service by Newswire.com

Original Source: MedBridge Launches New OASIS-E Comprehensive Excellence Certificate Program

The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists will Gather for the 2023 Tandem Meetings to Improve the Lives of Patients with Blood-Related Disorders and Solid Tumors.

CHICAGO - November 30, 2022 - (Newswire.com)

The 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® will connect the international community of hematopoietic cell transplantation and cellular therapy specialists for in-person and virtual programming. The 2023 Tandem Meetings are a joint partnership hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research® (CIBMTR), Feb. 15-19, 2023, in Orlando, Florida.

The Tandem Meetings connect a global community of more than 4,000 attendees to address multidisciplinary aspects of transplantation, cell therapy and gene therapy, including contemporary principles in nursing, pharmacy, data management, clinical research analysis, pediatric transplantation and transplant and/or cell therapy center administration.

The 2023 Tandem Meetings provide multiple registration options to expand the reach of the scientific program, which shares state-of-the-art advances, new methods and controversial issues in clinical management that impact the field. Attendees can choose to experience the meetings in person or virtually via live stream sessions. All attendees will have access to session recordings and continuing education credits during and after the conclusion of the meetings.

"The 2023 Tandem Meetings will bring together the brightest minds in our field," says Brenda M. Sandmaier, MD, ASTCT President. "I am grateful that ASTCT and CIBMTR are also livestreaming the scientific program, giving greater access to healthcare providers around the world."

"It can be challenging to translate new evidence into practice," says John Wingard, MD, CIBMTR Advisory Committee Chair, "yet this is crucial to improve our patients' health."

More information is available on the Tandem Meetings website. Members of the press are invited to attend the meetings in person or virtually. Follow #Tandem23 for the latest updates on the 2023 Tandem Meetings.

###

About American Society for Transplantation and Cellular Therapy (ASTCT)

ASTCT is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education, and clinical practice in the field. For more information about ASTCT, visit www.astct.org and follow ASTCT on Twitter @ASTCT.

About the Center for International Blood and Marrow Transplant Research® (CIBMTR) 

The CIBMTR is a research collaboration between the National Marrow Donor Program/Be The Match and the Medical College of Wisconsin. The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database. Learn more at cibmtr.org, and follow the CIBMTR on Twitter @CIBMTR.

Contact Information:
Jennifer Kasowicz
ASTCT Director of Marketing
[email protected]
312-673-4970




Press Release Service by Newswire.com

Original Source: The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists Will Gather for the 2023 Tandem Meetings

Symposia program provides distinctive CE events tailored to help dentists expand their practice horizons in 2023 and beyond.

NEWPORT BEACH, Calif. - November 30, 2022 - (Newswire.com)

Glidewell has announced its 2023 Glidewell Symposia program, featuring impactful continuing education opportunities on everything from implant dentistry and dental sleep medicine to digital dentistry and business management. Held throughout the year at the Glidewell Clinical Education Center in Irvine, California, the program consists of distinctive two-day events specifically tailored to help dental professionals expand their practice horizons in 2023 and beyond.

"I'm so happy to once again host Glidewell Symposia on our campus," said Glidewell Founder and President Jim Glidewell, CDT. "For more than 50 years, our goal at Glidewell has been to assist in better, faster, more accessible care — and we've worked toward this objective first as a dental laboratory, then as a materials manufacturer, and today as an education center, research facility, technological innovator and so much more. Having worked with tens of thousands of dentists over the years, we have unique insight into the everyday challenges of the practitioner, and we strive to do everything in our power to help dentists solve those issues, grow their practices and treat more patients in need."

The Glidewell Symposium launched in 2017 to help dentists learn new skills in making dental treatment more predictable, efficient and reliable than ever before. Since its inaugural event, Glidewell has been listening to attendees and applying the feedback received each year to create an exceptional experience. Now, with even more clinical topics, more business advice, more leadership development opportunities and more hands-on workshops, the 2023 schedule provides a wide variety of events for dentists at any stage in their careers. The upcoming calendar includes: 

• Implants: The Surgical Phase (March 24-25) 
  • Explore the surgical aspects of implant placement.
• Sleep: Building Your Practice with Dental Sleep Medicine (April 21-22)
  • Learn the modern dentist's role in sleep dentistry.
• Esthetics: Creating Beautiful Smiles (June 23-24)
  • Identify techniques and materials for achieving esthetic makeovers.
• Complete Dentures: Mastering the Foundational Skills (July 28-29)
  • Discover the future of removables in the dental practice.
• IOX: The Digital Dentistry Experience (August 18-19) 
  • Integrate the latest in digital chairside technology.
• Women on the Rise: Elevating Digital Dentistry (September 22-23)
  • Incorporate digital technology into every aspect of your practice.
• Implants: The Restorative Phase (October 13-14)
  • Examine the restorative aspects of implant dentistry.

While each event is distinct, all symposia have one thing in common: a popular two-day educational format. On the first day, attendees will experience fast-paced, main podium presentations from experts in the field; and on the second day, participants can choose from a variety of focused lectures and hands-on workshops that teach immediately implementable skills. 

"The mission of the Glidewell Symposia is to provide focused educational programs to keep dentists informed about the latest techniques, technologies and trends in dentistry — with a level of insight unique to the world's largest dental lab," said Jim Glidewell. "Each event offers impactful content and resources with takeaways that you can immediately integrate into your practice. I invite dental professionals to come join us. Previous attendees have assured us these events are a memorable experience."

The official launch of the program will begin with the first event "Implants: The Surgical Phase" on March 24-25. This Implant Symposium will provide two days of clinical and business education in the surgical phase of implant dentistry, and participants will receive nine CE hours. The first day of the event will feature concise, powerful and practical presentations with renowned experts — such as Drs. Randolph Resnik, Timothy Kosinski, Jack Hahn and Roger Levin — and on the second day, participants can select either an in-depth lecture or a workshop with hands-on exercises designed to help clinicians enhance their surgical skills. Topics available on the second day include the following:

• Socket preservation
• Guided surgery from start to finish
• Full-arch guided surgery and immediate provisionalization
• Placing small-diameter implants
• Sinus grafting

Glidewell Symposia are for dentists, hygienists, and chairside and front-office team members. Enrollment is now open for the Implant Symposium on March 24-25; preregistration is available for all other events. Tuition is $495 for each two-day event, and attendees can use promo code GL23 to receive $100 off registration. Tuition includes complimentary breakfast and lunch on both days, as well as a campus tour and a hosted cocktail party and dinner on Friday. Participants will also be able to browse interactive exhibits during both days of the event. Due to limited space, attendees are encouraged to register or preregister early to secure their seats. For details about the symposia schedule and to enroll, call 866-791-9539 or visit glidewellsymposium.com.

Contact Information:
Eldon Thompson
Sr. Director of Marketing
[email protected]


Press Release Service by Newswire.com

Original Source: Glidewell Announces Action-Packed 2023 Educational Symposia Schedule

Interoperability connections now enable nearly 200 million people to get their health records.

LOS ALTOS, Calif. - November 30, 2022 - (Newswire.com)

Mpowered Health, a healthcare marketplace, today announced that its platform is now live with interoperability connections to more than 1000+ health plans and health systems across the United States. 

Organizations connected to the platform include health systems, Medicare Advantage and Medicaid plans across the country, including national payers, blues and regional plans. With this update, nearly 200 million people across the country can now use the Mpowered Health App to access their medical records, coverage and explanation of benefits information from all these plans and health systems. In addition, the platform delivers a personalized shopping experience for consumers seeking to enroll in Medicare and exchange health plans. Mpowered Health is the first healthcare platform in the United States to offer consumers such convenience at scale. (View the list of all connections here).

"Mpowered Health is committed to empowering people to take control of their health information and experience. Since 2021, Mpowered Health began to unlock healthcare data for consumers through connections to My Medicare, Veterans Administration and Apple Health kit," says Nandini Devi, founder and CEO of Mpowered Health. "With this expanded network of 1000+ connections, consumers can assemble their most complete health record yet — all with a few clicks."

Consumers can also now share their records with their doctors, family members, caregivers and payers. "We also recently launched the xChange to enable healthcare organizations to accept records from these consumers with their consent via APIs," continues Devi. "We are pleased to be the first in the industry to offer such a convenience to all healthcare organizations and to all consumers irrespective of their age, gender or coverage."

Founded in 2019, Mpowered Health is a rapidly growing healthcare marketplace that provides a convenient platform for healthcare organizations to acquire, engage and retain consumers while giving consumers a voice, the transparency, the choice, the access and the convenience they need to manage their own and their family's health care.

Mpowered Health was featured in the Inc Magazine and CIO Today in 2022 and as one of the Top Healthcare Interoperability Solution Providers by Healthcare TechOutlook.

About Mpowered Health

Mpowered Health is a consumer-driven healthcare technology company committed to creating a better healthcare experience for consumers and healthcare enterprises. The California-based company empowers consumers to take charge of their healthcare by providing mobile-led solutions that improve transparency, choice, access and convenience. The company, in recognizing that consumer empowerment cannot be a zero-sum game, provides enterprise solutions in compliance, consumer acquisition and engagement to enable healthcare organizations to serve their consumers more effectively and achieve their organizational goals.

For more information, visit us at www.mpoweredhealth.com.

Media Contact: [email protected]

Contact Information:
Mpowered Health
Press
[email protected]


Press Release Service by Newswire.com

Original Source: Mpowered Health Expands Consumer Access to Medical Records With Connections to 1000+ Health Plans and Health Systems

Professional Employer Organization Heavyweight Acquires Nationwide Service Provider with a Focus on Servicing Small and Mid-Size Clients

CHICAGO - November 30, 2022 - (Newswire.com)

The changing needs of the labor market in today's climate have created a demand for PEO and OD services, and a growing reliance on outsourced support of these offerings, especially among mid-sized companies (50-500 people). To help meet this need, Salo Doko, a Professional Employer Organization (PEO) and Organizational Development (OD) executive with over a decade of experience supporting small, mid-size and enterprise-level companies is pleased to announce the acquisition of EvolveHR, with an emphasis on expanding the company's physical presence in Chicago and the Midwest. 

Founded in 2005 by Norman and Darryl LeClair, EvolveHR is a national service provider in the Professional Employer Organization (PEO) industry, with clientele located in the Midwest and Southeast regions of the country. The company provides human resources, payroll, benefits administration, technology and risk and liability management to small, midsize and enterprise clients. 

With the acquisition, Doko will build on EvolveHR's well-respected reputation of superior client service and frictionless support and will focus his priorities on several areas including: attracting top-tier talent, implementing new technologies for client efficiencies and enhancing the company's organizational development (OD) offering, which is geared toward assisting companies preparing to scale through the development of organizational structure, role clarity, culture definition and people development programs. 

"The job market has been unpredictable recently and with so many changes hitting the market, the value of a trusted partner to navigate HR and organizational structure needs has never been higher," said Salo Doko, owner, EvolveHR. "EvolveHR is a well-positioned company that is ripe for growth. Built off the hard work of the company's leadership team, the future is bright for continued expansion." 

The acquisition comes after an 18-month sabbatical for Doko, who previously served in the role of President at a large Chicago-based PEO for 10 years. Doko took the time to carefully look for the right opportunity to move into the next phase of his career.

The acquisition of EvolveHR was completed in November 2022 with a leadership transition effective immediately. EvolveHR is a national service provider with its main geographical focus in the Midwest and Southeastern regions with a physical presence in Chicago, IL, and St. Petersburg, FL. For more information, please visit www.EvolveHR.com. 

About EvolveHR

EvolveHR's services are based on three pillars - The People, The Consulting and The Technology. It provides HR, payroll, benefits administration, technology and risk and liability management to small, midsize and enterprise clients. Part of its services includes an OD offering which provides project-based solutions that assess, develop, and monitor the organizations of growing companies.

Organizations and HR can be complex, and EvolveHR is the partner that works shoulder-to-shoulder with its clients to enable alignment and allow its leaders to gear their efforts toward growing their business while EvolveHR facilitates the people matters. For more information, please visit www.EvolveHR.com.

Contact:

EvolveHR

[email protected]

https://www.linkedin.com/company/evolvehr-peo

Contact Information:
Brenda Rowan
VP, Client Services
[email protected]


Press Release Service by Newswire.com

Original Source: Chicago Executive Salo Doko Acquires EvolveHR